7:48 PM
 | 
Jul 28, 2017
 |  BioCentury  |  Finance

Potentiator potential

Why Pfizer Venture Investments led Effector's $38.6M series C

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor.

On July 24, Effector closed a $19.3 million first tranche of a $38.6 million series C round led by new investor Pfizer Venture Investments. The second and final tranche is slated to close in 2018. The trigger is undisclosed.

New investor Alexandria Venture Investments and existing investors U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The...

Read the full 418 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >